恶性肿瘤患者应用细胞因子诱导的杀伤细胞治疗后不良反应分析

王津; 江朝光; 韩为东; 王瑶; 卢学春; 刘洋; 张宝和; 王吉; 张燕; 丰恺超; 张文英; 陈美霞; 汪宣驰

doi:10.3969/j.issn.2095-5227.2013.06.027

恶性肿瘤患者应用细胞因子诱导的杀伤细胞治疗后不良反应分析

Adverse reactions in patients with malignant tumor after treatment with cytokine-induced killer cells

摘要

摘要: 目的观察细胞因子诱导的杀伤细胞(cytokine-induced killer，CIK)治疗恶性肿瘤中出现的不良反应、不良反应出现的可能原因及针对性治疗措施。方法回顾分析2008年3月-2012年10月730例恶性肿瘤患者回输CIK细胞悬液后各种不良反应的临床表现、实验室检查结果、采取的治疗措施及分析可能的原因。结果 CIK细胞回输后的不良反应有：发热(6.85%)、皮疹(1.64%)、消化道不适(0.96%)、关节疼痛(0.41%)、类过敏样反应及溶瘤综合征(均为0.14%)、类全身炎症反应综合征样反应(0.68%)，除合并血压下降、严重过敏样反应及溶瘤综合征需对症处理外，余无需特殊处理。不良反应原因可能与CIK细胞的归巢特征及个体差异有关。结论此疗法是安全有效的过继免疫治疗方法，相关不良反应经积极对症处理后可恢复。

Abstract: Objective To study the causes and countermeasures of adverse reactions in patients with malignant tumor after treatment with cytokine-induced killer (CIK) cells. Methods Clinical manifestations, laboratory findings, treatment measures and causes of adverse reactions in 730 patients with malignant tumor after treated with CIK cells from March 2008 to October 2012 were retrospectively analyzed. Results The main adverse reactions after infusion of CIK cells were fever(6.85%), rash(1.64%), digestive discomfort(0.96%), arthralgia (0.41%), anaphylactoid reaction (0.14%), tumor lysis syndrome (0.14%), and systemic inflammatory response syndrome reaction (0.68%).All the side effects were not specifically treated except for hypotension, severe anaphylactoid reaction and tumor lysis syndrome.The adverse reactions were related with the homing characteristics of CIK cells and individual difference. Conclusion CIK cells therapy is a safe and effective adoptive immunotherapy for malignant tumor and its adverse reactions can be treated expectantly.

HTML全文

参考文献(0)

施引文献

资源附件(0)